Next Article in Journal
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Next Article in Special Issue
The Multifunctional Protein Kinase C-ε in Cancer Development and Progression
Previous Article in Journal
Head and Neck Sarcomas: A Comprehensive Cancer Center Experience
Open AccessArticle

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

1
Centre for Chromosome Biology, School of Natural Sciences National University of Ireland Galway, Galway, Ireland
2
Department of Medicine, National University of Ireland Galway, Galway, Ireland
3
Department of Haematology, Galway University Hospital, Galway, Ireland
4
Nerviano Medical Sciences S.r.l., Via Pasteur 10, Nerviano 20014, Italy
*
Authors to whom correspondence should be addressed.
Present address: Boehringer Ingelheim RCV GmbH & Co KG, Vienna 1120, Austria
Cancers 2013, 5(3), 901-918; https://doi.org/10.3390/cancers5030901
Received: 5 June 2013 / Revised: 4 July 2013 / Accepted: 4 July 2013 / Published: 24 July 2013
(This article belongs to the Collection Kinases and Cancer)
Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors are effective in a variety of preclinical cancer models. These compounds also inhibit CDK9 which is relevant for MCL-1 expression. The activity and mechanism of action of the dual CDC7/CDK9 inhibitor PHA-767491 was assessed in a panel of multiple myeloma cell lines, in primary samples from patients, in the presence of stromal cells and in combination with drugs used in current chemotherapeutic regimens. We report that in all conditions myeloma cells undergo cell death upon PHA-767491 treatment and we report an overall additive effect with melphalan, bortezomib and doxorubicin, thus supporting further assessment of targeting CDC7 and CDK9 in multiple myeloma. View Full-Text
Keywords: apoptosis; BCL2-family; DNA replication; multiple myeloma; kinase inhibitor; cell cycle apoptosis; BCL2-family; DNA replication; multiple myeloma; kinase inhibitor; cell cycle
Show Figures

Figure 1

MDPI and ACS Style

Natoni, A.; Coyne, M.R.E.; Jacobsen, A.; Rainey, M.D.; O'Brien, G.; Healy, S.; Montagnoli, A.; Moll, J.; O'Dwyer, M.; Santocanale, C. Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models. Cancers 2013, 5, 901-918.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop